Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences
February 25 2015 - 4:10PM
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that
corporate presentations will be delivered at the following upcoming
investor conferences:
Cowen and Company 35th
Annual Health Care Conference (Boston, MA)
Presenter: Greg Madison, President and Chief Operating Officer
Presentation Date: Monday, March 2nd, 2015 Presentation Time: 4:50
pm ET
27th Annual ROTH
Conference (Dana Point, CA) Presenter: Abraham
Ceesay, VP, Marketing and Operations Presentation Date: Monday,
March 9th, 2015 Presentation Time: 9:00 am PT (12:00 noon ET)
Live audio webcasts of these presentations will be accessible
within the Investor Relations section of the Company's Website at
http://investors.keryx.com. An archived version of each webcast
will be available following the conclusion of the live
presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, headquartered in New York, is focused
on bringing innovative therapies to market for patients with renal
disease. The Company launched its first FDA-approved product,
Auryxia, in the United States in December 2014. In January 2014,
ferric citrate was approved for the treatment of patients with all
stages of CKD in Japan, where it is being marketed as Riona® by
Keryx's Japanese partner, Japan Tobacco Inc. and Torii
Pharmaceutical Co. Ltd. For more information about Keryx, please
visit www.keryx.com.
CONTACT: Amy Sullivan, Vice President - Corporate Development
and Public Affairs
Keryx Biopharmaceuticals, Inc.
Tel: 617.466.3447
E-mail: amy.sullivan@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2023 to Apr 2024